** Shares of drug developer Atea Pharmaceuticals AVIR.O rise 6.9% to $3.72 premarket
** Co says its drug combination met the main goal for treating Hepatitis C Virus (HCV) in a mid-stage study
** The combination of bemnifosbuvir and ruzasvir showed 98% success rate in eliminating HCV, co says
** Bemnifosbuvir and ruzasvir are both oral antiviral medications to treat HCV
** HCV is a leading cause of chronic liver diseases and liver transplants, affecting around 50 mln people worldwide
** As of last close, stock had risen 14.1% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.